Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation has introduced “Mounjaro® subcutaneous injection 2.5 mg / 5 mg ATEOS®”.
The world's first long-acting GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors.
The structure of the Mounjaro is based on a single molecule natural GIP peptide sequence, modified to bind to the GLP-1 receptor, and selectively acts for a long time to improve blood glucose. Mounjaro is a new class of treatment options for many people living with type 2 diabetes who need it.
Mounjaro with a single-use auto-injector (ATEOS) is delivered once in a week as a subcutaneous injection. The needle is inserted automatically consisting of a special pen with a pre-installed needle pressing the injection button under the skin and a single dose of the filled drug is injected with this needle. This injection does not require the patient to set the dose or handle the needle.
